1. Home
  2. INCY
  3. INCY News

Latest Incyte Corp. (INCY) News on November 23, 2024

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock
INCY

Insider Monkey

a day ago

Goldman Sachs: Incyte Corporation (INCY) Is A Top Growth Investor Stock

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
INCY

Zacks

2 days ago

Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More

INCY

Morningstar Research

3 days ago

Analyst Report: Incyte Corporation

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict
INCY

MT Newswires

4 days ago

Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict

INCY

MT Newswires

4 days ago

Equity Markets Close Mixed Ahead of Nvidia Earnings

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing
INCY

Investopedia

4 days ago

S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing

INCY

MT Newswires

4 days ago

Sector Update: Health Care Stocks Decline

INCY

MT Newswires

4 days ago

Top Midday Decliners

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict
INCY

MT Newswires

4 days ago

Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict

INCY

MT Newswires

4 days ago

Incyte Shares Drop After Disclosing Pause in Skin Disorder Study Due to Toxicology Findings

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study
INCY

Zacks

4 days ago

Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.
INCY

Investor's Business Daily

4 days ago

Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.

INCY

MT Newswires

4 days ago

RBC Cuts Price Target on Incyte to $74 From $80, Keeps Sector Perform Rating

INCY

Morningstar Research

4 days ago

Analyst Report: Incyte Corporation

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs
INCY

Business Wire

5 days ago

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?
INCY

Insider Monkey

5 days ago

Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
INCY

Insider Monkey

7 days ago

Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects

INCY

Morningstar Research

8 days ago

Analyst Report: Incyte Corporation

Incyte to Present at Upcoming Investor Conference
INCY

Business Wire

9 days ago

Incyte to Present at Upcoming Investor Conference

INCY

MT Newswires

9 days ago

RBC Raises Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating

INCY

MT Newswires

9 days ago

RBC Capital Adjusts Price Target on Incyte to $80 From $72, Keeps Sector Perform Rating

INCY

MT Newswires

15 days ago

Incyte Insider Sold Shares Worth $293,210, According to a Recent SEC Filing

INCY

Morningstar Research

16 days ago

Analyst Report: Incyte Corporation

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

16 days ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Bank of America Turns Bullish on These 2 Lesser-Known Stocks
INCY

TipRanks

17 days ago

Bank of America Turns Bullish on These 2 Lesser-Known Stocks

Syndax agrees funding with Royalty Pharma for Niktimvo US sales
INCY

Pharmaceutical Technology

18 days ago

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

BMRN vs. INCY: Which Stock Is the Better Value Option?
INCY

Zacks

19 days ago

BMRN vs. INCY: Which Stock Is the Better Value Option?

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
INCY

Benzinga

24 days ago

Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock

INCY

MT Newswires

24 days ago

Deutsche Bank Adjusts Price Target on Incyte to $70 From $61

INCY

MT Newswires

24 days ago

Morgan Stanley Adjusts Price Target on Incyte to $69 From $64

INCY

MT Newswires

24 days ago

JPMorgan Adjusts Price Target on Incyte to $71 From $65

INCY

MT Newswires

24 days ago

Goldman Sachs Adjusts Price Target on Incyte to $70 From $63

INCY

MT Newswires

24 days ago

Oppenheimer Adjusts Price Target on Incyte to $82 From $81

INCY

MT Newswires

24 days ago

Leerink Partners Adjusts Price Target on Incyte to $87 From $85

INCY

MT Newswires

24 days ago

Piper Sandler Adjusts Price Target on Incyte to $82 From $80

INCY

MT Newswires

24 days ago

Argus Adjusts Price Target on Incyte to $80 From $75

Incyte to Present at Upcoming Investor Conferences
INCY

Business Wire

24 days ago

Incyte to Present at Upcoming Investor Conferences

INCY

Argus Research

24 days ago

Analyst Report: Incyte Corp.

Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
INCY

Simply Wall St.

24 days ago

Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

INCY

Argus Research

24 days ago

Market Digest: NVS, BRO, ECL, F, GLW, INCY, TMUS, PFE, PKG, RSG

INCY

MT Newswires

24 days ago

BofA Upgrades Incyte to Buy From Neutral, Adjusts Price Target to $90 From $68

Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
INCY

GuruFocus.com

24 days ago

Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

INCY

Thomson Reuters StreetEvents

24 days ago

Q3 2024 Incyte Corp Earnings Call

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
INCY

Investor's Business Daily

25 days ago

Incyte Breaks Out To 17-Month High As Jakafi Demand Surges

INCY

MT Newswires

25 days ago

Stifel Raises Incyte's Price Target to $75 From $73

INCY

MT Newswires

25 days ago

Jefferies Raises Incyte's Price Target to $84 From $81

INCY

MT Newswires

25 days ago

RBC Raises Incyte's Price Target to $72 From $67

INCY

MT Newswires

25 days ago

BofA Securities Upgrades Incyte to Buy From Neutral, $90 Price Target

Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted
INCY

GuruFocus.com

25 days ago

Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted

INCY

MT Newswires

25 days ago

Wells Fargo Adjusts Price Target on Incyte to $68 From $62, Maintains Equalweight Rating

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
INCY

Benzinga

25 days ago

Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura

INCY

MT Newswires

25 days ago

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

Incyte (INCY) Q3 Earnings Miss Estimates
INCY

Zacks

25 days ago

Incyte (INCY) Q3 Earnings Miss Estimates

INCY

MT Newswires

25 days ago

Incyte Q3 Non-GAAP Net Income Falls, Revenue Rises

INCY

Associated Press Finance

25 days ago

Incyte: Q3 Earnings Snapshot

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
INCY

Business Wire

25 days ago

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

INCY

MT Newswires

a month ago

Leerink Partners Adjusts Price Target on Incyte to $85 From $84, Maintains Outperform Rating

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
INCY

Business Wire

a month ago

Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List

INCY

MT Newswires

a month ago

JPMorgan Chase Adjusts Price Target on Incyte to $65 From $61

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know
INCY

Zacks

a month ago

Incyte Gears Up to Report Q3 Earnings: Here's What You Should Know

State Street Corp's Strategic Reduction in Incyte Corp Holdings
INCY

GuruFocus.com

a month ago

State Street Corp's Strategic Reduction in Incyte Corp Holdings

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico
INCY

GlobeNewswire

a month ago

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

INCY

MT Newswires

a month ago

Wells Fargo Adjusts Price Target on Incyte to $62 From $63

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
INCY

Business Wire

a month ago

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

GMAB or INCY: Which Is the Better Value Stock Right Now?
INCY

Zacks

a month ago

GMAB or INCY: Which Is the Better Value Stock Right Now?

Incyte to Report Third Quarter Financial Results
INCY

Business Wire

2 months ago

Incyte to Report Third Quarter Financial Results

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

2 months ago

Guggenheim Adjusts Price Target on Incyte to $92 From $86

INCY

MT Newswires

2 months ago

Goldman Sachs Adjusts Incyte Price Target to $63 From $60

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

INCY

MT Newswires

2 months ago

Guggenheim Adjusts Price Target on Incyte to $86 From $92

INCY

MT Newswires

2 months ago

Wolfe Research Initiates Coverage on Incyte With Outperform Rating, $84 Price Target

INCY

Argus Research

2 months ago

The Argus Mid-Cap Model Portfolio

High Growth Tech Stocks To Watch For Future Potential
INCY

Simply Wall St.

2 months ago

High Growth Tech Stocks To Watch For Future Potential

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?
INCY

Zacks

2 months ago

Incyte Gains 12.7% Year to Date: How Should You Play the Stock?

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
INCY

Business Wire

2 months ago

Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress

INCY

MT Newswires

2 months ago

Deutsche Bank Lifts Price Target on Incyte to $61 From $60, Maintains Hold Rating

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease
INCY

PR Newswire

2 months ago

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
INCY

Benzinga

2 months ago

Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets

INCY

MT Newswires

2 months ago

Update: Truist Securities Downgrades Incyte to Hold From Buy, Cuts Price Target to $74 From $83

INCY

MT Newswires

2 months ago

Truist Securities Downgrades Incyte to Hold From Buy, Adjusts Price Target to $74 From $83

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
INCY

Investor's Business Daily

2 months ago

Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers

INCY

MT Newswires

2 months ago

Incyte Insider Sold Shares Worth $526,948, According to a Recent SEC Filing

Incyte Announces Promising New Data on Oncology Candidate at ESMO
INCY

Zacks

2 months ago

Incyte Announces Promising New Data on Oncology Candidate at ESMO

INCY

MT Newswires

2 months ago

Guggenheim Adjusts Incyte Price Target to $92 From $86, Maintains Buy Rating

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
INCY

Business Wire

2 months ago

Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
INCY

Business Wire

2 months ago

Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INCY

Business Wire

2 months ago

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?
INCY

Zacks

3 months ago

Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?

Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?
INCY

Zacks

3 months ago

Why Is Glaxo (GSK) Up 10.3% Since Last Earnings Report?

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?
INCY

Zacks

3 months ago

Incyte (INCY) Up 0.9% Since Last Earnings Report: Can It Continue?

Exploring Three High Growth Tech Stocks In The United States
INCY

Simply Wall St.

3 months ago

Exploring Three High Growth Tech Stocks In The United States

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024
INCY

Business Wire

3 months ago

Incyte to Present Late-Breaking Phase 3 Results for Retifanlimab (Zynyz®) and Initial Data from Phase 1 CDK2 Inhibitor Program at the European Society of Medical Oncology (ESMO) Congress 2024

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug
INCY

Zacks

3 months ago

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Armed with Phase III win, Incyte eyes label expansion for Monjuvi
INCY

Pharmaceutical Technology

3 months ago

Armed with Phase III win, Incyte eyes label expansion for Monjuvi

INCY

MT Newswires

3 months ago

Sector Update: Health Care Stocks Lean Lower Premarket Friday

INCY

MT Newswires

3 months ago

Incyte Cancer Treatment Candidate Meets Primary Goal in Study

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma
INCY

Business Wire

3 months ago

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®) in Relapsed or Refractory Follicular Lymphoma

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo
INCY

Pharmaceutical Technology

3 months ago

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
INCY

Benzinga

3 months ago

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

Share on Social Networks: